Knockdown of nuclear-retained long noncoding RNAs using modified DNA antisense oligonucleotides

Methods in Molecular Biology

Volumn 1262, Issue , 2015, Pages 321-331

  Zong, Xinying ^a   Huang, Lulu ^a   Tripathi, Vidisha ^a   Peralta, Raechel ^a   Freier, Susan M ^a   Guo, Shuling ^a   Prasanth, Kannanganattu V ^a  

^a NONE

Author keywords

Chemically modified chimeric DNA antisense oligonucleotides (ASO); Electroporation; Free uptake; In vivo delivery; Knockdown; Lipid transfection; Long noncoding RNAs (lncRNAs); Nuclear retained long noncoding RNAs (nr lncRNAs)

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; COMPLEMENTARY DNA; LONG UNTRANSLATED RNA; MESSENGER RNA;

ARTICLE; COMPUTER MODEL; CONTROLLED STUDY; ELECTROPORATION; IN VITRO STUDY; IN VIVO STUDY; PRIORITY JOURNAL; SYNTHESIS; ANIMAL; CELL LINE; CELL NUCLEUS; CHEMISTRY; GENE SILENCING; GENETICS; HELA CELL LINE; HEPG2 CELL LINE; HUMAN;

MAMMALIA;

ANIMALS; CELL LINE; CELL NUCLEUS; GENE KNOCKDOWN TECHNIQUES; HELA CELLS; HEP G2 CELLS; HUMANS; OLIGONUCLEOTIDES, ANTISENSE; RNA, LONG NONCODING; RNA, MESSENGER, STORED;

EID: 84921790730     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4939-2253-6_20     Document Type: Article

References (26)

1. Batista PJ, Chang HY (2013) Long noncoding RNAs: cellular address codes in development and disease. Cell 152(6):1298–1307
2. Nagano T, Fraser P (2011) No-nonsense functions for long noncoding RNAs. Cell 145(2): 178–181
3. Rinn JL, Chang HY (2012) Genome regulation by long noncoding RNAs. Annu Rev Biochem 81:145–166
4. Singh DK, Prasanth KV (2013) Functional insights into the role of nuclear-retained long noncoding RNAs in gene expression control in mammalian cells. Chromosome Res 21(6–7): 695–711
5. Nakagawa S, Kageyama Y (2014) Nuclear lncRNAs as epigenetic regulators-Beyond skepticism. Biochim Biophys Acta 1839(3):215–222
6. Tripathi V et al (2010) The nuclear-retained noncoding RNA MALAT1 regulates alternative splicing by modulating SR splicing factor phosphorylation. Mol Cell 39(6):925–938
7. Tripathi V et al (2013) Long noncoding RNA MALAT1 controls cell cycle progression by regulating the expression of oncogenic transcription factor B-MYB. PLoS Genet 9(3): e1003368
8. Gagnon KT, Li L, Chu Y, Janowski BA, Corey DR (2014) RNAi factors are present and active in human cell nuclei. Cell Rep 6(1):211–221
9. Billy E, Brondani V, Zhang H, Muller U, Filipowicz W (2001) Specific interference with gene expression induced by long, doublestranded RNA in mouse embryonal teratocarcinoma cell lines. Proc Natl Acad Sci U S A 98(25):14428–14433
10. Zeng Y, Cullen BR (2002) RNA interference in human cells is restricted to the cytoplasm. RNA 8(7):855–860
11. Kawasaki H, Taira K (2003) Short hairpin type of dsRNAs that are controlled by tRNA(Val) promoter significantly induce RNAi-mediated gene silencing in the cytoplasm of human cells. Nucleic Acids Res 31(2):700–707
12. Chiu YL, Ali A, Chu CY, Cao H, Rana TM (2004) Visualizing a correlation between siRNA localization, cellular uptake, and RNAi in living cells. Chem Biol 11(8):1165–1175
13. Crooke ST (1999) Molecular mechanisms of action of antisense drugs. Biochim Biophys Acta 1489(1):31–44
14. Vickers TA et al (2003) Efficient reduction of target RNAs by small interfering RNA and RNase H-dependent antisense agents. A comparative analysis. J Biol Chem 278(9):7108–7118
15. Ideue T, Hino K, Kitao S, Yokoi T, Hirose T (2009) Efficient oligonucleotide-mediated degradation of nuclear noncoding RNAs in mammalian cultured cells. RNA 15(8):1578–1587
16. Lima WF et al (2007) Human RNase H1 discriminates between subtle variations in the structure of the heteroduplex substrate. Mol Pharmacol 71(1):83–91
17. Koller E et al (2011) Mechanisms of singlestranded phosphorothioate modified antisense oligonucleotide accumulation in hepatocytes. Nucleic Acids Res 39(11):4795–4807
18. Zhang B et al (2012) The lncRNA Malat1 is dispensable for mouse development but its transcription plays a cis-regulatory role in the adult. Cell Rep 2(1):111–123
19. Graham MJ et al (2007) Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice. J Lipid Res 48(4):763–767
20. Hung G et al (2013) Characterization of target mRNA reduction through in situ RNA hybridization in multiple organ systems following systemic antisense treatment in animals. Nucleic Acid Therapeut 23(6):369–378
21. Butler M et al (2005) Spinal distribution and metabolism of 2′-O-(2-methoxyethyl)-modified oligonucleotides after intrathecal administration in rats. Neuroscience 131(3):705–715
22. Passini MA et al (2011) Antisense oligonucleotides delivered to the mouse CNS ameliorate symptoms of severe spinal muscular atrophy. Sci Transl Med 3:72ra18
23. Grillone LR, Lanz R (2001) Fomivirsen. Drugs Today (Barc) 37(4):245–255
24. Geary RS, Henry SP, Grillone LR (2002) Fomivirsen: clinical pharmacology and potential drug interactions. Clin Pharmacokinet 41(4):255–260
25. Seth PP et al (2010) Synthesis and biophysical evaluation of 2′,4′-constrained 2′O-methoxyethyl and 2′,4′-constrained 2′O-ethyl nucleic acid analogues. J Org Chem 75(5):1569–1581
26. Ostergaard ME et al (2013) Rational design of antisense oligonucleotides targeting single nucleotide polymorphisms for potent and allele selective suppression of mutant Huntingtin in the CNS. Nucleic Acids Res 41(21):9634–9650